2 research outputs found
Out with the old and in with the new: T90 codends improve size selectivity in the Canadian redfish (Sebastes mentella) trawl fishery
The size selectivity of four codends were compared in the Gulf of St. Lawrence, Canada, redfish fishery (Sebastes mentella), including the regulated diamond mesh codend with a mesh opening of 90 mm (T0) and three experimental codends of different mesh openings (90, 100, 110 mm) in which the netting is turned 90° to the direction of tow (T90). Results for the regulated codend showed that there was little size selection, catching greater than 97% of redfish over all of the length classes observed. Considering the fished population, the smallest T90 codend would catch 30% fewer redfish under the minimum landing size (MLS) of 22 cm compared with the T0 codend, but would also lose 16% of catch above 22 cm. The T90 codend with 100 mm mesh opening had the same size selectivity as the smallest T90 codend. The 110 mm T90 codend would catch 50% less redfish below MLS but lose 40% of redfish above MLS. Overall, results show that T90 codends improve size selectivity in which large proportions of undersized fish are successfully released.The accepted manuscript in pdf format is listed with the files at the bottom of this page. The presentation of the authors' names and (or) special characters in the title of the manuscript may differ slightly between what is listed on this page and what is listed in the pdf file of the accepted manuscript; that in the pdf file of the accepted manuscript is what was submitted by the author
Recommended from our members
Aspirin Effects on Mortality and Morbidity in Patients With Diabetes Mellitus: Early Treatment Diabetic Retinopathy Study Report 14
Objectives.—This report presents information on the effects of aspirin on mortality, the occurrence of cardiovascular events, and the incidence of kidney disease in the patients enrolled in the Early Treatment Diabetic Retinopathy Study (ETDRS).Study Design.—This multicenter, randomized clinical trial of aspirin vs placebo was sponsored by the National Eye Institute.Patients.—Patients (N=3711) were enrolled in 22 clinical centers between April 1980 and July 1985. Men and women between the ages of 18 and 70 years with a clinical diagnosis of diabetes mellitus were eligible. Approximately 30% of all patients were considered to have type I diabetes mellitus, 31% type II, and in 39% type I or II could not be determined definitely.Intervention.—Patients were randomly assigned to aspirin or placebo (two 325-mg tablets once per day).Main Outcome Measures.—Mortality from all causes was specified as the primary outcome measure for assessing the systemic effects of aspirin. Other outcome variables included cause-specific mortality and cardiovascular events.Results.—The estimate of relative risk for total mortality for aspirin-treated patients compared with placebo-treated patients for the entire study period was 0.91 (99% confidence interval, 0.75 to 1.11). Larger differences were noted for the occurrence of fatal and nonfatal myocardial infarction; the estimate of relative risk was 0.83 for the entire follow-up period (99% confidence interval, 0.66 to 1.04).Conclusions.—The effects of aspirin on any of the cardiovascular events considered in the ETDRS were not substantially different from the effects observed in other studies that included mainly nondiabetic persons. Furthermore, there was no evidence of harmful effects of aspirin. Aspirin has been recommended previously for persons at risk for cardiovascular disease. The ETDRS results support application of this recommendation to those persons with diabetes at increased risk of cardiovascular disease.(JAMA. 1992;268:1292-1300